Fig. 3

The FIT-039 administration rescued the PEL malignancy in the xenograft model. A The schema of the PEL xenograft study. The BCBL-1 cells were intraperitoneally (i.p.) inoculated in NOD/SCID mice, followed by i.p. administration of the vehicle or FIT-039 (75, 150, or 300 mg/kg-BW), thrice a week (t.i.w.). B Representative pictures of the mice at day 45. Bars, 1 cm. C FCM plot for ascites from the vehicle-treated mice at day 43. Plots for PE-human CD38 and APC-human CD45 (left) and isotype controls (right) are shown. D Pictures of the ascites and immunochemistry for RTA are shown. Bars, 50 µm. E-F The ascites volume (E) and total cell number (F) are plotted for PEL xenograft mice treated with the FIT-039 at 0, 75, 150, and 300 mg/kg-BW, i.p., t.i.w. for 43 days. G Live cell rates of xenografted BCBL-1 in ascites (0 or 75 mg/kg-BW i.p. administration of FIT-039) are determined by FCM through FSC-SSC plot of human CD38 (hCD38)-positive cells. H Length of the spleens from the BCBL-1 xenograft mice after FIT-039 administration (0, 75, 150, or 300 mg/kg-BW) for 43 days are plotted. Spleen lengths of the age-adjusted control mice, without the xenograft or the administration of the 0.5% MC or FIT-039, are also indicated. I Pictures of spleens from FIT-039-administered mice were shown. Bar indicates 1 cm. J Body weights of NOD/SCID mice administered with 300 mg/kg-BW FIT-039 or vehicle t.i.w., without the inoculation of BCBL-1 xenograft. n = 10, 10, 9, and 10 for 0, 75, 150, and 300 mg/kg-BW in (E) and (F), n = 10, 10, 9, and 10 for 0, 75, 150, and 300 mg/kg-BW, and n = 6 for the group without the xenograft or FIT-039 administration in (H), and n = 6 for vehicle and 300 mg/kg-BW in (J). mpk for mg/kg-BW in (A-J). Mean ± SE are shown; n.s., p ≥ 0.05; ***, p < 0.001 by one-way ANOVA with Turkey’s multiple comparisons test in (E), (F) and (H). Mean ± SE are shown; n.s., p ≥ 0.05 by two-tailed Student’s t-test in (G) and (J)